Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

Avera and Avera Health Plans transitioned to a new combined patient and member portal as of May 30, 2026. If you haven’t already, create an account and reset your proxy access. Learn how to sign up at Avera.org/MyChart.

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (4)

Showing 1-4 of 4

Sorted By:

A-Z
Z-A

Previous Next

A022102: Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
BGB-B455-101: A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors
Ph 1 Open-Label Study Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Prelim Antitumor Activity of BGB-B455 in Pts w/Selected Adv/Met Solid Tumors
BI 1479-0012 (Beamion BCGC-1): A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)
Phase II Trial of Oral Zongertinib Alone/Combo W/Other Agents for Pts w/Adv HER2+ mBC, met. Gastric, GJ, mGEAC, or mCRC
D9803C00001 CLARITY-Gastric02: A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Ph 3 Study of Sonesitatug vedotin in Combination w/Capecitabine w/wo Rilvegostomig in 1st line Claudin18.2-positive,HER2-, Adv/Met Gastric,GEJ,orEsophageal Adenocarcinoma

Previous Next